哈工智能(000584.SZ):擬變更對參股公司設序科技的會計核算方法
格隆匯 1 月 17日丨哈工智能(000584.SZ)公佈,公司第十一屆董事會第十四次會議決議,審議通過《關於對參股公司會計核算方法變更的議案》。
公司參股公司上海設序科技有限公司(“設序科技”)完成天使輪融資,導致公司持股比例下降至20%以下,鑑於公司持有設序科技股權比例進一步稀釋,對其影響進一步減弱;且公司不再參與其經營活動,實質上失去對設序科技的重大影響,根據《企業會計準則》的相關規定,同意公司變更對設序科技股權投資的會計核算方法,由按權益法計量的長期股權投資變更為以公允價值計量且其變動計入當期損益的金融資產,以更加合理、準確地反映公司對設序科技投資的會計核算情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.